Navigation Links
New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias
Date:12/6/2010

omes evaluated in the study included overall survival, progression-free survival, failure-free survival, and event-free survival.

At different key milestones throughout the study, the CCgR rate was high (78 percent at three months, 96 percent at six, 12, and 18 months). Within 12 months, the cumulative CCgR rate for study participants was 100 percent, which means that all patients achieved CCgR at least once. Additionally, after a median follow-up of 36 months, overall survival, progression-free survival, and failure-free survival reached 99 percent for each, and event-free survival was 92 percent. The cumulative major molecular response (MMR) rate, a more sensitive measurement of response, was 96 percent at 12 months. The MMR rate was 52 percent at three months, 66 percent at six months, 85 percent at one year, 81 percent at 18 months, and 82 percent at two years. In patients who achieved an MMR, none progressed to accelerated or blast phase CML. Furthermore, only one patient in the entire study progressed to accelerated or blast phase due to the development of another BCR-ABL mutation called a T315I mutation.

"While it is important to rapidly induce responses in these patients, it is also important that these responses last as long as possible," said lead study author Gianantonio Rosti, MD, Scientific Secretary of the GIMEMA CML WP, Department of Hematology and Oncology, University of Bologna, Bologna, Italy. "Results from this study not only show that nilotinib quickly induces high rates of response, but responses also are durable and stable beyond three years, translating into optimal outcomes for newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia."

Dr. Rosti will present this study in an oral presentation on Monday, December 6, at 10:30 a.m. in Room Valencia D.

A Phase I Trial of Oral Ponatinib (AP24534) in Patients With Refractory Chronic Myelogenous Leukemia (CML) and O
'/>"/>

Contact: Lindsey Love
llove@hematology.org
540-538-9326
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. MSU researcher linking breast cancer patients with alternative therapies
2. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
3. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
4. NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)
5. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
6. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
7. Study evaluates costs and benefits associated with new colon cancer therapies
8. New therapies increase survival rates in post-transplant liver cancer patients
9. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
10. Molecular discovery points to new therapies for brain tumors
11. Ovarian cancer study offers vital clues for new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... investment, announced the two leaders who will deliver keynote presentations at the upcoming ... the Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO of Optum, will ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Blincyto® (blinatumomab) – in the news recently following a decision by the Centers ... patients – is likely to average approximately $71,000 or roughly 40% of its ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Officer following the departure of Kristen Dietz, former Chief Operations Officer. Shaun ... the following statement welcoming Mr. Salot: “ Stanley H. Salot Jr , our ...
(Date:9/2/2015)... ... 2015 , ... Good health and a good cause paired up at The ... BCBSNJ) donated $11,000 to the New Jersey Golf Foundation through its Healthy Steps Challenge. ... The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... at Children's Healthcare of Atlanta to help support childhood cancer research. On ... upcoming WSB Radio Care-A-Thon , which is the fund-raising event DoMyOwnPestControl.com sponsors ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:Healtec® Announces Executive Leadership Change 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2
... a gene that appears to increase a person,s risk ... of the disease. The gene, abbreviated as MTHFD1L, is ... association study. Details are published September 23 in the ... of researchers was led by Margaret A. Pericak-Vance, PhD, ...
... of motorcycle crashes were 1.5 times more likely to ... though many more of the African-American victims were wearing ... new study by Johns Hopkins researchers. Results of ... August issue of the American Journal of Surgery ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. 23 ... use and texting soared in the space of three years, ... alone caused more than 16,000 deaths in car accidents from ... cell phones and texting while driving rose 28 percent in ...
... Cancer Center have discovered a new cell signaling pathway ... when defective, helps promote the formation of several major ... The new pathway, part of a global DNA damage ... are known to cause cancer because, unchecked, they can ...
... Nursing professor, Dr. Diane Doran, was awarded more than ... safety of over 900,000 Canadians who receive health care ... Patient Safety Institute and its partners announced today the ... of Canada,s leading healthcare researchers. The selected research team ...
... a well-crafted football play designed to block the opposing ... constantly executes complex ,plays, or sequences of events to ... Scientists at the University of Rochester Medical Center recently ... the unwanted enlargement of the heart and a well-known ...
Cached Medicine News:Health News:Team of researchers finds possible new genetic risk for Alzheimer's disease 2Health News:Black motorcyclists -- even in helmets -- more likely to die in crashes 2Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Molecular 'playbook' for halting heart failure risk factor uncovered 2
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has ... China (Basel, Switzerland - November 26-27, 2015)" conference to ... detailed overview of the key areas of pharmaceutical regulatory affairs ... , Macau and ... All important aspects of gaining and maintaining a successful Marketing ...
(Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rf2c5p/an_introduction ) has announced ... the Medical Devices Directive (London, UK - November ... This seminar provides a detailed introduction ... explain the Directives and which products are covered, ... one and outline what a manufacturer must do. ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2
... 21 Sorrento Therapeutics, Inc. (OTC Bulletin Board: ... Technology Small Business Technology Transfer Research (STTR) grant from ... peer-reviewed grant was awarded to support the Company,s program ... to combat Staphylococcus aureus ( S. aureus ...
... , WASHINGTON , May 20 The owner and ... to defrauding the Medicare program, announced the Departments of Justice and Health ... , , ... to commit health care fraud before U.S. District Judge David Hittner ...
Cached Medicine Technology:Sorrento Therapeutics Awarded NIH Grant for MRSA Program 2Sorrento Therapeutics Awarded NIH Grant for MRSA Program 3Sorrento Therapeutics Awarded NIH Grant for MRSA Program 4Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 2Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 3
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, ... its space saving, 2-level design. Up to 27 ... to give you the flexibility to tailor your ... lab. Two start stations allow for continuous loading; ...
... latest from the leader in automatic slide ... modern approach to slide staining, ending messy ... blood smears, bone marrow and other body ... Aerospray stainer becomes a superb cytocentrifuge with ...
Medicine Products: